Biocon Launches Yesafili, an Interchangeable Eylea Biosimilar, in U.S.

BENGALURU, India and BRIDGEWATER, N.J. — Biocon Limited announced today the commercial launch of Yesafili (aflibercept-jbvf) in the United States, marking a pivotal expansion of the company’s ophthalmology portfolio. Yesafili is an interchangeable biosimilar to Regeneron’s Eylea (aflibercept) 2 mg, a widely used vascular endothelial growth factor (VEGF) inhibitor.

The launch, effective August 3, 2026, introduces a competitive alternative to the high-value U.S. ophthalmic market, where aflibercept sales reached approximately $5.89 billion in 2023. By securing an interchangeable designation from the U.S. Food and Drug Administration (FDA), Yesafili allows for pharmacy-level substitution in accordance with state laws, potentially streamlining access for patients.

Expanding Access to Eye Care

Yesafili is indicated for the treatment of several critical ocular conditions, including neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR). With approximately 19.8 million Americans aged 40 and older estimated to be living with AMD—a leading cause of irreversible vision loss—the introduction of a more accessible biosimilar is expected to have a broad impact on patient care.

"The launch of Yesafili in the U.S. marks an important step in expanding the global availability of biosimilar Aflibercept 2 mg for patients with eye conditions," said Shreehas Tambe, CEO and Managing Director of Biocon Ltd. "This milestone further strengthens our presence in ophthalmology and builds on our FDA approval as one of the first interchangeable biosimilars to Eylea 2 mg."

Clinical Foundation and Regulatory Status

The FDA’s approval of Yesafili, first granted in May 2024, was predicated on a comprehensive suite of analytical, nonclinical, and clinical data. Central to this evidence was the Phase 3 INSIGHT study, which compared the biosimilar to the reference product, Eylea 2 mg, in patients with diabetic macular edema. The study confirmed that there were no clinically meaningful differences between the two in terms of pharmacokinetics, safety, efficacy, and immunogenicity.

While the vial formulation of Yesafili holds full interchangeable status, the company has noted that its pre-filled syringe presentation carries a provisional interchangeability status.

Official Sources

Information regarding this commercial launch is based on formal announcements provided by Biocon Limited. Regulatory history and approval details have been verified through U.S. FDA records and industry filings.

Quote Section

"The launch of Yesafili in the U.S. marks an important step in expanding the global availability of biosimilar Aflibercept 2 mg for patients with eye conditions," stated Shreehas Tambe, CEO & Managing Director, Biocon Ltd.

Why It Matters

The entry of an interchangeable biosimilar into the U.S. market for a high-cost drug like Eylea is a significant development for the healthcare system. By providing a lower-cost, clinically equivalent alternative that pharmacists can substitute automatically, this launch is designed to reduce the financial burden on both patients and healthcare providers while maintaining high standards of clinical care for sight-threatening conditions.

Key Facts at a Glance

• Product: Yesafili (aflibercept-jbvf), an interchangeable biosimilar to Eylea 2 mg.

• Launch Date: August 3, 2026.

• Key Indications: Neovascular (wet) AMD, macular edema following RVO, diabetic macular edema, and diabetic retinopathy.

• Regulatory Milestone: Granted interchangeable designation by the FDA in May 2024, allowing for pharmacy-level substitution.

• Market Impact: Targets a U.S. market where aflibercept saw approximately $5.89 billion in sales in 2023.

FAQ

What does "interchangeable biosimilar" mean for patients? An interchangeable biosimilar is a product that has been shown to produce the same clinical result as the reference product. Because it is designated as interchangeable, it may be substituted for the reference product at the pharmacy without the intervention of the prescribing healthcare provider, subject to state laws.

What conditions does Yesafili treat? Yesafili is indicated for neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR).

Is Yesafili identical to Eylea? Yesafili is a biosimilar, meaning it is highly similar to Eylea with no clinically meaningful differences in safety, purity, or potency, and it has been proven to be interchangeable for the 2 mg dose.

Source: Biocon Limited, U.S. Food and Drug Administration